GlassScriptPhysician profile
John G Heise
NPI 1962405787
$1,102.50
in general payments reported to CMS, 2019-2025
30 companies · $64.05 in 2025
The $64.05 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $23.70 · 2021: $34.65 · 2022: $198 · 2023: $408 · 2024: $272 · 2025: $64.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $94.70 | 2023 | Triptodur |
| Ascendis Pharma Endocrinology INC | $93.43 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $89.50 | 2021-2024 | Supprelin |
| Greenwich Biosciences, INC. | $86.74 | 2019 | |
| Abbott Laboratories | $81.45 | 2022-2024 | Freestyle Libre 3 |
| Mallinckrodt Hospital Products INC. | $56.43 | 2024 | Acthar |
| Zealand Pharma US, INC. | $50.51 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $38.45 | 2022 | |
| Kyowa Kirin, INC. | $35.03 | 2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $33.88 | 2022-2024 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $32.46 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.33 | 2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $27.85 | 2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Corium, LLC | $27.25 | 2023 | Azstarys |
| Organon LLC | $26.37 | 2025 | Nexplanon |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.63 | 2024 | |
| Beta Bionics, INC. | $23.81 | 2023 | Ilet Bionic Pancreas |
| Ipsen Biopharmaceuticals, INC | $23.70 | 2020 | |
| Endo USA, INC. | $22.86 | 2024 | Supprelin |
| Verrica Pharmaceuticals INC. | $22.41 | 2024 | Ycanth |
| Sanofi Pasteur INC. | $22.17 | 2025 | |
| Becton, Dickinson and Company | $21.65 | 2022 | |
| Tandem Diabetes Care, INC. | $20.65 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $19.87 | 2024 | |
| Glaxosmithkline, LLC. | $18.53 | 2023 | Rotarix, Pediarix, Bexsero |
| Insulet Corporation | $18.19 | 2023 | Omnipod |
| Pfizer INC. | $15.69 | 2023 | |
| Eton Pharmaceuticals, INC. | $15.51 | 2025 | Galzin, Nitisinone, Carglumic Acid |
| Novo Nordisk INC | $15.11 | 2019 | |
| Abbvie INC. | $13.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Heise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.